title: Chloride secretagogues stimulate inositol phosphate formation in shark rectal gland tubules cultured in suspension.
abstract: Neuroendocrine activation of transepithelial chloride secretion by shark rectal gland cells is associated with increases in cellular cAMP, cGMP, and free calcium concentrations. We report here on the effects of several chloride secretagogues on inositol phosphate formation in cultured rectal gland tubules. Vasoactive intestinal peptide (VIP), atriopeptin (AP), and ionomycin increase the total inositol phosphate levels of cultured tubules, as measured by ion exchange chromatography. Forskolin, a potent chloride secretagogue, has no effect on inositol phosphate formation. The uptake of 3H-myo-inositol into phospholipids is very slow, preventing the detection of increased levels of inositol trisphosphate. However, significant increases in inositol monophosphate (IP1) and inositol biphosphate (IP2) were measured. The time course of VIP- and AP-stimulated IP1 and IP2 formation is similar to the effects of these agents on the short-circuit current responses of rectal gland monolayer cultures. In addition, aluminum fluoride, an artificial activator of guanine nucleotide-binding proteins, stimulates IP1 and IP2 formation. We conclude that rectal gland cells contain VIP and AP receptors coupled to the activation of phospholipase C. Coupling may be mediated by G-proteins. Receptor-stimulated increases in inositol phospholipid metabolism is one mechanism leading to increased intracellular free calcium concentrations, an important regulatory event in the activation of transepithelial chloride secretion by shark rectal gland epithelial cells.
authors.affiliation: Department of Physiology and Cell Biology, University of Texas Medical School, Houston 77225.
authors.forename: T W
authors.initials: TW
authors.lastname: Ecay
authors.forename: J D
authors.initials: JD
authors.lastname: Valentich
mesh_terms: D000535:Aluminum / Q000494:pharmacology; D017607:Aluminum Compounds; D000818:Animals; D009320:Atrial Natriuretic Factor / Q000494:pharmacology; D001692:Biological Transport; D002478:Cells, Cultured; D002712:Chlorides / Q000378:metabolism / Q000502:physiology*; D004284:Dogfish / Q000378:metabolism* / Q000502:physiology; D004847:Epithelial Cells; D004848:Epithelium / Q000378:metabolism; D005459:Fluorides / Q000494:pharmacology; D007294:Inositol / Q000378:metabolism / Q000493:pharmacokinetics; D007295:Inositol Phosphates / Q000378:metabolism*; D015759:Ionomycin / Q000494:pharmacology; D010743:Phospholipids / Q000378:metabolism; D012491:Salt Gland / Q000378:metabolism*; D015290:Second Messenger Systems / Q000502:physiology; D014316:Tritium; D014660:Vasoactive Intestinal Peptide / Q000494:pharmacology
chemical_list: D017607:Aluminum Compounds; D002712:Chlorides; D007295:Inositol Phosphates; D010743:Phospholipids; D014316:Tritium; D014660:Vasoactive Intestinal Peptide; D007294:Inositol; D015759:Ionomycin; D009320:Atrial Natriuretic Factor; D000535:Aluminum; D005459:Fluorides; C032311:aluminum fluoride